Drug Utilization Review Board Minutes

May 25, 2016

The West Virginia Medicaid Drug Utilization Review (DUR) Board meeting was called to order with the following in attendance:

Members Present:

Lester Labus, MD, Chair
K.C. Lovin, PA-C, Vice Chair
C.K. Babcock, PharmD
Christopher Booth, PharmD
Scott Brown, RPh
Myra Chiang, MD
Karen Fitzpatrick, MD
Kate Forman, PharmD
Michael Lonsinger, Pharm D
Ernest Miller, DO
Mary Nemeth-Pyles, MSN, RN, CS
Chris Terpening, PharmD, PhD
John Vanin, MD

DHHR/BMS Staff Present

Vicki Cunningham, RPh, Director of Pharmacy Services
Brian Thompson, MS, PharmD, DUR Coordinator
Bill Hopkins, Pharmacy Operations Manager
Doug Sorvig, Administrative Assistant

Contract Staff

Steve Small, MS, RPh, Rational Drug Therapy Program (RDTP)
Eric Sears, RPh, Molina Medicaid Solutions
Brent Breeding, RPh, Goold Health Systems
Mark Garofoli, PharmD, MBA, Rational Drug Therapy Program (RDTP)
Matthew Waldrop, PharmD, Health Information Designs (HID)

I. INTRODUCTIONS

A. Dr. Lester Labus, Chairman, welcomed everyone to the Board meeting (4:07 p.m., EDT). The DUR Board and attendees introduced themselves. A motion was made, seconded, and approved to accept the minutes from the previous DUR Board meeting.

II. OLD BUSINESS

A. Repatha / Praluent criteria – A motion to approve the criteria as presented was made, seconded and passed.

III. NEW BUSINESS

A. **Speakers: 2 speakers**

1.	Dr. Bassam Haffar	Gastroenterologist (Non-industry)	Viberzi
2.	Joseph Loftus	Novo Nordisk	Tresiba
3.	James Hammond	Alkermes	Aristada

B. **Updates from the April 27th, 2016 Pharmacy & Therapeutics Committee Meeting**

1. Dr. Labus and the Board reviewed the updates from the April 27th P&T meeting. No criteria changes were requested beyond those presented in section III-C of this document. (Attachment A)

C. **PDL Prior-Authorization Criteria** (Attachment B)

1. **Aristada** – A motion to approve criteria as presented was made, seconded and passed.

2. **Antiretrovirals Class** – A motion to approve criteria as presented was made, seconded and passed.
   a. **Stribild** – non-preferred agent
   b. **Triumeq** – non-preferred agent
   c. **Complera** – non-preferred agent

3. **Humira and Enbrel** – A motion to approve criteria as presented was made, seconded and passed.

4. **Pulmicort Respules –** A motion to approve criteria as presented was made, seconded and passed.

5. **Tresiba –** Upon Board request, the following revisions were made to the criteria presented:

> "Tresiba U-100 will be authorized only for patients with a 6-month history of compliance on preferred long-acting insulin. Tresiba U-200 and Toujeo Solostar will only be approved for patients with a 6-month history of compliance on preferred long-acting insulin who require once-daily doses of at least 60 units of insulin."

A motion to approve the revised criteria was made, seconded and passed.

6. **Viberzi –** A motion to approve criteria as presented was made, seconded and passed.

7. **Suboxone/Subutex –** Upon Board request, the following revisions were made to criteria #6 in the document presented:

"Buprenorphine tablets may only be approved for use during pregnancy or in the case of a well-documented and clinically verified life-threatening allergy to naloxone*

Naloxone allergy documentation MUST include a detailed description of symptoms. (Life threatening allergic reactions are generally considered to be anaphylactic in nature, Stevens-Johnson syndrome or DRESS). "

A motion to approve the revised criteria was made, seconded and passed.

8. **Ciprodex otic drops –** The Board was notified about a recent change in our age limit. A PA is no longer required for patients older than 9 years of age.

IV. REPORTS

A. **Molina Quarterly Report – First Quarter 2016** – Eric Sears presented an overview of the Molina 2016 First Quarter Report. The presentation included a review of the DUR Quarterly Overall Summary Report. (Attachment C)

B. **Rational Drug Therapy Program** – Stephen Small presented a review of the prior authorization program for the First Quarter 2016. The presentation included prior authorization approval rates, edit overrides, distribution, and therapeutic duplications. (Attachment D)

C. **Health Information Designs** – Matthew Waldrop presented an overview of the First Quarter 2016 retrospective drug utilization activity. The presentation indicated the number of profiles reviewed, letters mailed to providers, rate of response, and evaluation of usefulness from the providers. The presentation also included an overview of activities in the Lock-In program and a completed educational intervention. (Attachment E)

V. OTHER BUSINESS – OPEN TO THE FLOOR

A. **Opioid and Pain Management Concepts** – Mark Garofoli presented an overview of the West Virginia Expert Pain Management Panel's Opioid PA Criteria Proposal, including morphine equivalents, summary of CDC Chronic Pain Opioid Guidelines, and proposed prior authorization phases. (Attachment F)

VI. NEXT MEETING AND ADJOURNMENT

A. A motion to adjourn the meeting was made, seconded, and passed.

B. The meeting concluded at 6:13 p.m., EDT.

C. The next meeting will be Wednesday, September 28th, 2016 from 4:00 p.m. – 6:00 p.m. and located at WVDHR.

Submitted:

Matthew Waldrop, PharmD, Health Information Designs.